Exemestane in metastatic breast cancer: effective therapy after third-generation non-steroidal aromatase inhibitor failure

N Steele, J Zekri, R Coleman, R Leonard, K Dunn, A Bowman, I Manifold, I Kunkler, O Purohit, D Cameron

Research output: Contribution to journalArticlepeer-review

Abstract

Exemestane is a potent steroidal aromatase inhibitor (AI) with activity in post-menopausal women with metastatic breast cancer, with a reported clinical benefit (CB) rate of 24.3% after prior AI therapy. Data on 114 patients (112 female, 2 male) were obtained retrospectively at two cancer centres. Sixty-five percent of patients were confirmed as oestrogen receptor (ER) positive. All patients had received prior third-generation AI therapy. Responses were seen in 5% and the overall CB rate (CR+PR+SD24 weeks) was 46%. Median PFS and OS were 18 and 61 weeks, respectively. In patients with visceral disease, the CBR was 33%. Patients with known ER-positive disease had a CBR of 47%, and a median TTP of 19 weeks. No benefit was seen in patients with known ER-negative disease. Survival was better in those with CB (median survival not reached in those with CB, 28 weeks in those without CB P
Original languageEnglish
Pages (from-to)430-6
Number of pages7
JournalThe Breast
Volume15
Issue number3
DOIs
Publication statusPublished - Jun 2006

Keywords

  • Androstadienes
  • Aromatase Inhibitors
  • Breast Neoplasms
  • Disease Progression
  • Female
  • Humans
  • Male
  • Receptors, Estrogen
  • Retrospective Studies
  • Treatment Failure

Fingerprint Dive into the research topics of 'Exemestane in metastatic breast cancer: effective therapy after third-generation non-steroidal aromatase inhibitor failure'. Together they form a unique fingerprint.

Cite this